MELA Sciences Announces the Results of its Third Clinical Advisory Meeting & the Four Clinical Posters Presented at the Winte...
January 22 2014 - 7:55AM
Business Wire
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an
FDA approved optical diagnostic device that assists dermatologists
in the diagnosis of melanoma, today announced the results of its
third company-sponsored Clinical Advisory meeting hosted during the
Winter Clinical Dermatology Conference in Hawaii where technical
advancements of MelaFind® and future technology development
opportunities were discussed and user’s validated its clinical use.
MELA Sciences also displayed four clinical posters presentations at
the conference, which took place from January 17 – 22, 2014.
The poster presentations reviewed clinical data derived from
practice and clinical settings that highlighted how MelaFind has
helped dermatologists in the assessment of clinically ambiguous
pigmented skin lesions in various patients including young adults,
an area of growing concern, and those with atypical mole syndrome.
To view the posters and their accompanying abstract please click
here.
The poster authored by Dr. Darrell Rigel, titled Physical
Properties, Novel Features and Clinical Validation of a
Multispectral Digital Skin Lesion Analysis Device for Melanoma, and
outlined below was named Poster of the Day on the first day of the
conference.
Highlights of the studies and the data shown in the poster
presentations are as follows:
Physical Properties, Novel Features and Clinical Validation
of a Multispectral Digital Skin Lesion Analysis Device (MSDSLA) for
Melanoma Detection - Darrell S. Rigel, MD, MS NYU School of
Medicine, New York, NY; Laura Ferris, MD, PhD, University of
Pittsburgh. Pittsburgh, PA; Arthur Sober, MD, Harvard University,
Boston, MA; Clay J. Cockerell, MD, University of Texas
Southwestern, Dallas, TX
- Retrospective data from the MelaFind
pivotal study was used to investigate the MelaFind multispectral
images and classifier score result as a tool to differentiate
cutaneous melanoma from other pigments skin lesions.
- Results showed the average classifier
scores of melanomas, high-grade lesions, non-melanoma skin cancers,
and histologically benign nevi were 3.5, 2.7, 2.6 and 1.6
respectively.
- Further results showed an increase in
the mean classifier score result with each additional clinical
characteristic present in the lesion.
Assessing the Predictive Probability of Melanoma and Other
High Risk Pigmented Lesions Using Data Provided by a Multispectral
digital Skin Lesion Analysis Device - Jane Yoo, MD, MPP, Dept.
of Dermatology, Albert Einstein School of Medicine, Bronx, NY;
Natalie Tucker, BS, MELA Sciences, Irvington, NY; Darrell S. Rigel,
MD, MS, Dept. of Dermatology, NYU School of Medicine, NYC, NY
- A risk prediction model was built to
assess the predictive probability of melanoma or a high-risk lesion
for consideration for biopsy based on data obtained from
MelaFind.
- Results show a potential quantitative
predictive capacity for presence of melanoma and other high risk
pigmented lesions using the MelaFind device.
In addition to presenting data from the four studies, MELA
Sciences held its third Clinical Advisory Meeting for current and
prospective MelaFind users and thought leaders. In attendance was
Dr. Antonanella Calame, dermatologist, dermatopathologist and
medical director of Compass Dermatology and Dermatopathology in La
Jolla, CA. Dr. Calame, a user of MelaFind, said, “As
dermatologists, one of our most important goals is diagnosing
melanoma, the deadliest form of skin cancer, at its earliest and
most curable stage. The MelaFind system’s images and data analysis
tools help dermatologists with one of the most challenging
questions we face each day when evaluating clinically ambiguous
pigments skin lesions: “Is this lesion atypical enough for me to
remove and investigate further via histology?” MelaFind’s analysis
of a lesion’s architectural structure gives us access to new
information deeper into the skin, where the human eye cannot see,
and helps us answer this critical question, improving overall
outcomes for both patient and clinician. These tools are available
for the first time in medicine and MelaFind is just the beginning.
If patient outcomes are our foremost concern, adoption of such
technologies should be widespread and soon become part of the
standard of care.”
The Winter Clinical Dermatology Conference was conducted over
four days and had nearly 400 participants from various fields of
dermatology, medical and cosmetic. In discussing the Advances in
the Diagnosis of Melanoma, Dr. Laura Ferris credited MelaFind as an
important instrument in helping to detect melanoma.
Please follow us:
Twitter:
@MELASciencesIR or @MelaFind
StockTwits:
@MELASciencesIR
Facebook:
www.facebook.com/MelaFind
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
flagship product is MelaFind®, an FDA, PMA and CE Mark approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible to
near-infrared light waves to evaluate skin lesions from the surface
to 2.5 mm beneath the skin. It provides images and data on the
relative disorganization of a lesion's structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA
is also exploring new potential uses for its core imaging
technology and algorithms.
Safe Harbor
This press release includes "forward-looking statements" within
the meaning of the Securities Litigation Reform Act of 1995. These
statements include but are not limited to our plans, objectives,
expectations and intentions and may contain words such as “seeks,”
“look forward,” and “there seems” that suggest future events or
trends. These statements are based on our current expectations and
are inherently subject to significant uncertainties and changes in
circumstances. Actual results may differ materially from our
expectations due to financial, economic, business, competitive,
market, regulatory and political factors or conditions affecting
the company and the medical device industry in general, as well as
more specific risks and uncertainties set forth in the company’s
SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any
or all of these forward-looking statements may prove to be
incorrect or unreliable. MELA Sciences assumes no duty to update
its forward-looking statements and urges investors to carefully
review its SEC disclosures available at www.sec.gov and
www.melasciences.com.
Media:MELA Sciences, Inc.Diana Garcia Redruello,
212-518-4226dgarcia@melasciences.comorInvestorsCatalyst
GlobalToni Trigiani or David Collins,
212-924-9800mela@catalyst-ir.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024